The structure-guided discovery of osimertinib: the first US FDA approved mutant selective inhibitor of EGFR T790M

被引：36
作者：
Butterworth, Sam [1 ]
Cross, Darren A. E. [1 ]
Finlay, Raymond V. [1 ]
Ward, Richard A. [1 ]
Waring, Michael J. [1 ]
机构：
[1] AstraZeneca, Darwin Bldg,310 Cambridge Sci Pk,Milton Rd, Cambridge CB4 0WG, England
来源：
MEDCHEMCOMM | 2017年 / 8卷 / 05期
关键词：
LUNG-CANCER; RESISTANCE; RECEPTOR; AZD9291;
D O I：
10.1039/c7md90012k
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：820 / 822
页数：3
相关论文
共 4 条
  • [1] AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
    Cross, Darren A. E.
    Ashton, Susan E.
    Ghiorghiu, Serban
    Eberlein, Cath
    Nebhan, Caroline A.
    Spitzler, Paula J.
    Orme, Jonathon P.
    Finlay, M. Raymond V.
    Ward, Richard A.
    Mellor, Martine J.
    Hughes, Gareth
    Rahi, Amar
    Jacobs, Vivien N.
    Brewer, Monica Red
    Ichihara, Eiki
    Sun, Jing
    Jin, Hailing
    Ballard, Peter
    Al-Kadhimi, Katherine
    Rowlinson, Rachel
    Klinowska, Teresa
    Richmond, Graham H. P.
    Cantarini, Mireille
    Kim, Dong-Wan
    Ranson, Malcolm R.
    Pao, William
    [J]. CANCER DISCOVERY, 2014, 4 (09) : 1046 - 1061
  • [2] Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor
    Finlay, M. Raymond V.
    Anderton, Mark
    Ashton, Susan
    Ballard, Peter
    Bethel, Paul A.
    Box, Matthew R.
    Bradbury, Robert H.
    Brown, Simon J.
    Butterworth, Sam
    Campbell, Andrew
    Chorley, Christopher
    Colclough, Nicola
    Cross, Darren A. E.
    Currie, Gordon S.
    Grist, Matthew
    Hassall, Lorraine
    Hill, George B.
    James, Daniel
    James, Michael
    Kemmitt, Paul
    Klinowska, Teresa
    Lamont, Gillian
    Lamont, Scott G.
    Martin, Nathaniel
    McFarland, Heather L.
    Mellor, Martine J.
    Orme, Jonathon P.
    Perkins, David
    Perkins, Paula
    Richmond, Graham
    Smith, Peter
    Ward, Richard A.
    Waring, Michael J.
    Whittaker, David
    Wells, Stuart
    Wrigley, Gail L.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (20) : 8249 - 8267
  • [3] Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
    Mok, T. S.
    Wu, Y. -L.
    Ahn, M. -J.
    Garassino, M. C.
    Kim, H. R.
    Ramalingam, S. S.
    Shepherd, F. A.
    He, Y.
    Akamatsu, H.
    Theelen, W. S. M. E.
    Lee, C. K.
    Sebastian, M.
    Templeton, A.
    Mann, H.
    Marotti, M.
    Ghiorghiu, S.
    Papadimitrakopoulou, V. A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (07) : 629 - 640
  • [4] Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)
    Ward, Richard A.
    Anderton, Mark J.
    Ashton, Susan
    Bethel, Paul A.
    Box, Matthew
    Butterworth, Sam
    Colclough, Nicola
    Chorley, Christopher G.
    Chuaqui, Claudio
    Cross, Darren A. E.
    Dakin, Les A.
    Debreczeni, Judit E.
    Eberlein, Cath
    Finlay, M. Raymond V.
    Hill, George B.
    Grist, Matthew
    Klinowska, Teresa C. M.
    Lane, Clare
    Martin, Scott
    Orme, Jonathon P.
    Smith, Peter
    Wang, Fengjiang
    Waring, Michael J.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (17) : 7025 - 7048
1